59
The pathway includes the receptor activator of the nuclear factor kappa-B (NF-κB) 60 ligand (RANKL), which is an osteoclast differentiation factor and receptor of the osteoclast differentiation genes ( VAN WIJNEN et al. 2013 We selected 10 candidate miRNAs, which were reportedly related to bone unchanged between patients with and without osteoporosis (Fig 2A, B, D) ; however, 226 the expression of SMAD4 and RANK was significantly upregulated in patients with 227 osteoporosis as compared to those without the disease (Fig 1C, E) respectively, compared with the negative control-transfected cells (Fig 3C) . These 254 data suggest that RANK is a miR-144-3p target in CD14+ PBMCs.
255
To validate this hypothesis, we cloned a WT and mutant (seed sequence) RANK
256
3′UTR into the pMir-reporter vector to generate a CMV-luciferase-WT and 257 CMV-luciferase-mutant RANK 3′UTR expression vector, respectively (Fig 3D) . failed to inhibit luciferase activity (Fig 3E) compared to RANK levels in the negative control (Fig 3F) . Together, these data 270 confirm RANK as a miRNA-144-3p target. increased TRAP activity, respectively, as compared with the negative control (Fig 4A) . with the negative control (Fig 4B-D) . These results suggest that miR-144-3p control group (Fig. 5A B) . These results demonstrated that miR-144-3p affects 294 osteoclast formation. M-CSF and RANKL. These cells were cultured for 6 days, and then subjected to 303 CCK-8 assay and flow cytometric analysis (Fig 5A) . 
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The results of the present study also identified SMAD4 as being differentially 220x66mm (300 x 300 DPI)
